对类固醇难治的炎症性肠病的药物治疗。
Pharmacologic therapy for inflammatory bowel disease refractory to steroids.
作者信息
Martínez-Montiel M P, Casis-Herce B, Gómez-Gómez G J, Masedo-González A, Yela-San Bernardino C, Piedracoba C, Castellano-Tortajada G
机构信息
Division of Gastroenterology, Hospital 12 de Octubre, Madrid, Spain.
出版信息
Clin Exp Gastroenterol. 2015 Aug 17;8:257-69. doi: 10.2147/CEG.S58152. eCollection 2015.
Abstract
Although corticosteroids are an effective treatment for induction of remission in inflammatory bowel disease (IBD), many patients are dependent on or refractory to corticosteroids. This review is based on scrutinizing current literature with emphasis on randomized controlled trials, meta-analyses, and Cochrane reviews on the management of IBD refractory to corticosteroids. Based on this evidence, we propose algorithms and optimization strategies for use of immunomodulator and biologic therapy in IBD refractory to corticosteroids.
摘要
尽管皮质类固醇是诱导炎症性肠病（IBD）缓解的有效治疗方法，但许多患者依赖皮质类固醇或对其难治。本综述基于对当前文献的仔细审查，重点关注关于皮质类固醇难治性IBD管理的随机对照试验、荟萃分析和Cochrane综述。基于这些证据，我们提出了在皮质类固醇难治性IBD中使用免疫调节剂和生物疗法的算法及优化策略。
相似文献
1
Pharmacologic therapy for inflammatory bowel disease refractory to steroids.对类固醇难治的炎症性肠病的药物治疗。
Clin Exp Gastroenterol. 2015 Aug 17;8:257-69. doi: 10.2147/CEG.S58152. eCollection 2015.
2
Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.与溃疡性结肠炎相关的泛发性坏疽性脓皮病：英夫利昔单抗和硫唑嘌呤治疗成功
Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5.
3
Efficacy of Combination Antibiotic Therapy for Refractory Pediatric Inflammatory Bowel Disease.联合抗生素治疗在儿童炎症性肠病中的疗效。
Inflamm Bowel Dis. 2019 Aug 20;25(9):1586-1593. doi: 10.1093/ibd/izz006.
4
Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.中重度炎症性肠病的常规治疗：系统文献回顾。
World J Gastroenterol. 2019 Mar 7;25(9):1142-1157. doi: 10.3748/wjg.v25.i9.1142.
5
The role and advances of immunomodulator therapy for inflammatory bowel disease.免疫调节剂治疗炎症性肠病的作用与进展
Expert Rev Gastroenterol Hepatol. 2015 Feb;9(2):177-89. doi: 10.1586/17474124.2014.945914. Epub 2014 Aug 7.
6
Methotrexate for induction of remission in refractory Crohn's disease.甲氨蝶呤用于诱导难治性克罗恩病缓解
Cochrane Database Syst Rev. 2012 Dec 12;12:CD003459. doi: 10.1002/14651858.CD003459.pub3.
7
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.用于维持克罗恩病缓解的肿瘤坏死因子-α抗体。
Cochrane Database Syst Rev. 2008 Jan 23(1):CD006893. doi: 10.1002/14651858.CD006893.
8
Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.英夫利昔单抗和其他抗肿瘤坏死因子 α 治疗药物治疗炎症性肠病。
BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000.
9
Methotrexate for induction of remission in ulcerative colitis.甲氨蝶呤用于诱导溃疡性结肠炎缓解
Cochrane Database Syst Rev. 2007 Oct 17(4):CD006618. doi: 10.1002/14651858.CD006618.pub2.
引用本文的文献
1
Food as Treatment of Inflammatory Bowel Diseases.食物作为炎症性肠病的治疗方法。
Infect Immun. 2022 May 19;90(5):e0058321. doi: 10.1128/iai.00583-21. Epub 2022 May 11.
2
Contrast Enhanced Ultrasound Molecular Imaging of Spontaneous Chronic Inflammatory Bowel Disease in an Interleukin-2 Receptor α Transgenic Mouse Model Using Targeted Microbubbles.使用靶向微泡对白细胞介素-2受体α转基因小鼠模型中自发性慢性炎症性肠病进行对比增强超声分子成像。
Nanomaterials (Basel). 2022 Jan 17;12(2):280. doi: 10.3390/nano12020280.
3
Current Use of EEN in Pre-Operative Optimisation in Crohn's Disease.EEN 在克罗恩病术前优化中的当前应用。
Nutrients. 2021 Dec 8;13(12):4389. doi: 10.3390/nu13124389.
4
Declining Use of Corticosteroids for Crohn's Disease Has Implications for Study Recruitment: Results of a Pilot Randomized Controlled Trial.克罗恩病患者使用皮质类固醇减少对研究招募的影响：一项随机对照试验的初步结果
J Can Assoc Gastroenterol. 2020 Nov 20;4(5):214-221. doi: 10.1093/jcag/gwaa037. eCollection 2021 Oct.
5
Real-life burden of adverse reactions to biological therapy in inflammatory bowel disease: a single-centre prospective case series.炎症性肠病生物治疗不良反应的实际负担：一项单中心前瞻性病例系列研究
Med Pharm Rep. 2021 Jul;94(3):289-297. doi: 10.15386/mpr-1897. Epub 2021 Jul 29.
6
Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis.免疫调节剂与维得利珠单抗联合用于溃疡性结肠炎维持缓解的潜在获益。
J Gastroenterol Hepatol. 2022 Jan;37(1):81-88. doi: 10.1111/jgh.15667. Epub 2021 Sep 7.
7
Therapeutic Potential of a Self-Assembling Peptide Hydrogel to Treat Colonic Injuries Associated with Inflammatory Bowel Disease.自组装肽水凝胶治疗炎症性肠病相关结肠损伤的治疗潜力。
J Crohns Colitis. 2021 Sep 25;15(9):1517-1527. doi: 10.1093/ecco-jcc/jjab033.
8
Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study.炎症性肠病患者合并症对 TNF-α 拮抗剂反应和复发的影响：VERNE 研究。
BMJ Open Gastroenterol. 2020 Mar 26;7(1):e000351. doi: 10.1136/bmjgast-2019-000351. eCollection 2020.
9
Macrophage-Specific NF-κB Activation Dynamics Can Segregate Inflammatory Bowel Disease Patients.巨噬细胞特异性 NF-κB 激活动力学可将炎症性肠病患者分类。
Front Immunol. 2019 Sep 11;10:2168. doi: 10.3389/fimmu.2019.02168. eCollection 2019.
10
Chronic Model of Inflammatory Bowel Disease in IL-10 Transgenic Mice: Evaluation with Ultrasound Molecular Imaging.白细胞介素-10转基因小鼠炎症性肠病的慢性模型：超声分子成像评估
Theranostics. 2019 Aug 14;9(21):6031-6046. doi: 10.7150/thno.37397. eCollection 2019.
本文引用的文献
1
Conventional drug therapy for inflammatory bowel disease.炎症性肠病的传统药物治疗
Scand J Gastroenterol. 2015 Jan;50(1):90-112. doi: 10.3109/00365521.2014.968864.
2
Long-term outcomes of thalidomide in refractory Crohn's disease.沙利度胺治疗难治性克罗恩病的长期疗效。
Aliment Pharmacol Ther. 2015 Mar;41(5):429-37. doi: 10.1111/apt.13057. Epub 2014 Dec 15.
3
The impact of timing and duration of thiopurine treatment on colectomy in ulcerative colitis: a national population-based study of incident cases between 1989-2009.硫唑嘌呤治疗的时机和持续时间对溃疡性结肠炎结肠切除术的影响：一项基于全国人群的1989 - 2009年新发病例研究。
Aliment Pharmacol Ther. 2015 Jan;41(1):87-98. doi: 10.1111/apt.13017. Epub 2014 Nov 10.
4
Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same?维得利珠单抗治疗炎症性肠病：改变游戏规则，还是换汤不换药？
United European Gastroenterol J. 2014 Oct;2(5):333-44. doi: 10.1177/2050640614550672.
5
Therapeutic drug monitoring in inflammatory bowel disease.炎症性肠病中的治疗药物监测
Ann Gastroenterol. 2014;27(4):304-312.
6
Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients.炎症性肠病持续临床缓解期硫嘌呤撤药情况：237例患者的复发率和重新用药率及预测因素
Aliment Pharmacol Ther. 2014 Dec;40(11-12):1313-23. doi: 10.1111/apt.12980. Epub 2014 Oct 6.
7
Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse.炎症性肠病中使用肿瘤坏死因子拮抗剂诱导治疗期间治疗药物监测的作用：原发性无反应的定义和管理的演变
Inflamm Bowel Dis. 2015 Jan;21(1):182-97. doi: 10.1097/MIB.0000000000000202.
8
Methotrexate for maintenance of remission in Crohn's disease.甲氨蝶呤用于维持克罗恩病的缓解状态
Cochrane Database Syst Rev. 2014 Aug 26;2014(8):CD006884. doi: 10.1002/14651858.CD006884.pub3.
9
Use of methotrexate in inflammatory bowel disease in 2014: A User's Guide.2014年甲氨蝶呤在炎症性肠病中的应用：用户指南
World J Gastrointest Pharmacol Ther. 2014 Aug 6;5(3):113-21. doi: 10.4292/wjgpt.v5.i3.113.
10
The role and advances of immunomodulator therapy for inflammatory bowel disease.免疫调节剂治疗炎症性肠病的作用与进展
Expert Rev Gastroenterol Hepatol. 2015 Feb;9(2):177-89. doi: 10.1586/17474124.2014.945914. Epub 2014 Aug 7.
Zotero 插件